Chia-Ping Huang Yang
Overview
Explore the profile of Chia-Ping Huang Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Yang C, Horwitz S, McDaid H
J Nat Prod
. 2022 Mar;
85(3):720-728.
PMID: 35240035
Photoaffinity labeling approaches have historically been used in pharmacology to identify molecular targets. This methodology has played a pivotal role in identifying drug-binding domains and searching for novel compounds that...
2.
Nadaradjane C, Huang Yang C, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, et al.
J Nat Prod
. 2018 Mar;
81(3):607-615.
PMID: 29522336
(+)-Discodermolide is a microtubule-stabilizing agent with potential for the treatment of taxol-refractory malignancies. (+)-Discodermolide congeners containing the C-3'-phenyl side chain of taxol (paclitaxel) were synthesized based on computational docking models...
3.
Huang Yang C, Wang C, Ojima I, Horwitz S
J Nat Prod
. 2018 Mar;
81(3):600-606.
PMID: 29517223
Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing βIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance. Using a...
4.
Huang Yang C, Horwitz S
Int J Mol Sci
. 2017 Aug;
18(8).
PMID: 28792473
Taxol, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature. This short review of the mechanism of action of Taxol emphasizes the research...
5.
Huang Yang C, Yap E, Xiao H, Fiser A, Horwitz S
Proc Natl Acad Sci U S A
. 2016 Sep;
113(40):11294-11299.
PMID: 27651486
There are seven β-tubulin isotypes present in distinct quantities in mammalian cells of different origin. Altered expression of β-tubulin isotypes has been reported in cancer cell lines resistant to microtubule...
6.
Seagle B, Huang Yang C, Eng K, Dandapani M, Odunsi-Akanji O, Goldberg G, et al.
Gynecol Oncol
. 2015 May;
138(1):159-64.
PMID: 25958320
Objective: To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs...
7.
ORourke B, Huang Yang C, Sharp D, Horwitz S
Cell Cycle
. 2014 Dec;
13(20):3218-21.
PMID: 25485501
Abstract Eribulin mesylate is a synthetic analog of halichondrin B known to bind tubulin and microtubules, specifically at their protein rich plus-ends, thereby dampening microtubule (MT) dynamics, arresting cells in...
8.
Albrethsen J, Angeletti R, Horwitz S, Huang Yang C
Mol Cancer Ther
. 2013 Nov;
13(1):260-9.
PMID: 24252851
Despite the clinical success of microtubule-interacting agents (MIA), a significant challenge for oncologists is the inability to predict the response of individual patients with cancer to these drugs. In the...
9.
Pellicciotta I, Huang Yang C, Venditti C, Goldberg G, Shahabi S
Cancer Cell Int
. 2013 Apr;
13(1):33.
PMID: 23574945
Background: Ovarian cancer constitutes nearly 4% of all cancers among women and is the leading cause of death from gynecologic malignancies in the Western world. Standard first line adjuvant chemotherapy...
10.
Miller L, Huang Yang C, Xiao H, Isaac S, Seve P, Dumontet C, et al.
Proteomics Clin Appl
. 2012 Sep;
6(9-10):502-6.
PMID: 22996942
Purpose: Quantitation of β-tubulin isotype expression in taxane resistant human tumor tissue has been difficult to achieve because of the limited availability of validated antibodies. Here we present a label-free...